Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1434868 · FYE Dec 31 · Prices AT CLOSE 2026-07-13 (USD) — end-of-day, never a live or intraday quote
Last $3.18Mkt cap $819M1Y +181.4%Off 52W high −23.8%Vol (1Y) 90.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,280 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.8% of sh out |
| Days to cover1.7d |
| 13F net flow (QoQ)+5.13% |
| Top-10 13F concentration58.5% |
| Next report (est.)2026-08-09 |
Short interest is FINRA semi-monthly, settlement 2026-06-30. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$418.2M |
| Earnings (TTM)-$7.4M |
| Net margin−5.6% |
| Sales growth 3Y74.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−14.1% |
| 1Y+181.4% |
| 3Y+113.4% |
| 5Y−82.0% |
| 10Y−71.5% |
| Since incept. (ann.)−11.0% |
Total return through 2026-07-13 · series begins 2013-06-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)90.6% |
| Ann. volatility (3Y)89.1% |
| Sharpe (1Y)1.51 |
| Sharpe (3Y)0.73 |
| Max drawdown (1Y)−53.2% |
| Max drawdown (3Y)−80.9% |
| Beta (3Y vs SPY)3.79 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 17.9M | $49M | 6.95% | +1.0% |
| WASATCH ADVISORS LP | 15.8M | $43M | 6.14% | +66.9% |
| Two Seas Capital LP | 11.4M | $31M | 4.44% | −4.3% |
| ORBIMED ADVISORS LLC | 10.6M | $29M | 4.12% | +77.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | 10.4M | $29M | 4.06% | new |
| TWO SIGMA INVESTMENTS, LP | 9.5M | $26M | 3.68% | +99.5% |
| MARSHALL WACE, LLP | 7.1M | $19M | 2.75% | +29.3% |
| STATE STREET CORP | 7.1M | $19M | 2.75% | +19.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-08 | −$0.10 | — | $80.1M | +23.2% |
| 2025-12-31 | 2026-03-10 | — | — | $168.4M | +143.7% |
| 2025-09-30 | 2025-11-06 | −$0.16 | — | $87.3M | +69.1% |
| 2025-06-30 | 2025-08-05 | −$0.06 | — | $82.4M | +11.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-09 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
